Show simple item record

dc.contributor.advisorMohi, Golam
dc.contributor.authorJOBE, FATOUMATA
dc.date.accessioned2021-07-30T18:43:22Z
dc.date.available2021-07-30T18:43:22Z
dc.date.issued2016
dc.identifier.urihttp://hdl.handle.net/20.500.12648/2019
dc.description.abstractMyeloproliferative neoplasms (MPNs) are a class of clonally-derived hematologic malignancies characterized by uncontrolled proliferation of myeloid lineage cells. Theyare classified into Philadelphiachromosome-positive (Ph+)MPNs, consisting of chronic myelogenous leukemia (CML), and Philadelphiachromosome-negative (Ph-)MPNs, consisting of polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis(PMF).The JAK2V617F mutation is the most common abnormality in Ph-MPNs, occurring in ~95% of PV patients, 55% of ET patients and 65% of PMF patients. JAK2V617F mutation results in constitutive activation of the JAK2 tyrosine kinase. Deletion of chromosome 20q (20q-) is a common chromosomal abnormality in myeloid neoplasms, including about 24%of MFcases. The 20q-lesion can coexist with JAK2V617Fmutation in MPN and MDS/MPN. The PTPN1gene is located on human chromosome 20q, within the commonly deleted region. PTPN1 is a tyrosine phosphatase and a known negative regulator of JAK-STAT signaling. The role of PTPN1 loss in the pathogenesis of MPNs and the mechanism by which loss of PTPN1 might contribute to various MPN phenotypes remains elusive. The goalsof this dissertation were to determine the effects of PTPN1 deficiency alone and in JAK2V617F-induced MPNs in vivo. To determine the mechanism by which PTPN1 mediates its tumor suppressor function using hematopoietic cells andassessment of PTPN1 status in 20q-MPN patients.Using conditional knock-out PTPN1 mouse model, we show that deletion of PTPN1 causes an MPN-like phenotype, characterized by increased WBC and NE counts and splenomegaly, compared to control mice. We also show that loss of PTPN1 causesfibrosis in older mice. PTPN1 knockdown significantly increased cell proliferation and activation of JAK2, MAPK and AKT signaling, whereas over expression in JAK2V617F-expressing cells attenuated cytokine-independent cell proliferation and signaling. Our data revealed a cooperative effect between PTPN1 deficiency and JAK2V617F expression in mice as shown by enhanced severity of theMPN phenotype and transformation to MF. Cell autonomous BMT revealed that the effects of PTPN1 deficiency are cell autonomous.Taken together, our results suggest a novel tumor suppressor function for PTPN1 in MPNs.en_US
dc.language.isoen_USen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTUMORen_US
dc.subjectSUPPRESSORen_US
dc.subjectFUNCTIONen_US
dc.subjectPTPN1en_US
dc.subjectMYELOPROLIFERATIVEen_US
dc.subjectNEOPLASMSen_US
dc.titleA TUMOR SUPPRESSOR FUNCTION FOR PTPN1 IN MYELOPROLIFERATIVE NEOPLASMSen_US
dc.typeDissertationen_US
dc.description.versionNAen_US
refterms.dateFOA2021-07-30T18:43:23Z
dc.description.institutionUpstate Medical Universityen_US
dc.description.departmentPharmacologyen_US
dc.description.degreelevelPhDen_US
dc.identifier.oclc1006654723


Files in this item

Thumbnail
Name:
Jobe.pdf
Size:
2.955Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International